ISTANBUL escrs

Thermal pulsation treatment for MGD and dry eye to optimize tear film for better quality of vision after laser refractive surgery or advanced technology lens implantation

Session Details

Session Title: Cornea
Session Date/Time: Sunday 22/02/2015 | 08:30-11:00
Paper Time: 09:15
Venue: Hall 2
First Author: : M.Piovella ITALY
Co Author(s): :    B. Kusa              

Abstract Details

Purpose:

To evaluate advanced technology devices for the thermal pulsation treatment of meibomian gland dysfunction(MGD) in evaporative dry eye patients.

Setting:

C.M.A. Centro Microchirurgia Ambulatoriale Monza- Milan- Italy

Methods:

80 eyes of 40 patients(mean age 52.69±15.57 years )were diagnosed with MGD based on the following criteria: results of a symptom questionnaire and quantification of the lipid layer thickness using interferometric color units (ICU) as determined by the LipiView (TearScience, Morrisville,NC - USA) and standardized meibomian gland expression to determine meibomian gland functionality. Criteria for treatment eligibility were LipiView score ≤ 70 ICU and meibonian gland function evaluation. Eligible patients received a LipiFlow treatment (TearScience, Morrisville, NC) designed to remove meibomian gland obstructions and restore meibomian gland function. Patients were reassessed - at 1-3-6 -12-18months and 2 years post treatment.

Results:

In all eyes, the symptoms had decreased at 1 - months post-treatment. The mean pre-treatment ICU score is increased from 53.00 ± 19.87 to 91.83 ± 12.37 at 2 year post-treatment. The AVG ICU showed 73.26% increase. Patients reported no discomfort or pain during or after treatment.

Conclusions:

This system provides an effective and efficient means of treatment for meibomian gland dysfunction and evaporative dry eye. For patients with MGD, this treatment should be considered prior to laser assisted refractive surgery or advanced technology lens implantation in order to optimize the tear film and thus optimize surgical outcomes.

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous